The UMCG website shows YouTube videos. YouTube places cookies if you watch them. Choose ‘Rather not’ if you do not want these cookies. We also place cookies of our own. These help us improve the usability of our website.
More on our cookie policy.
PREVEND
Prospective observational study with serial follow-up investigating predictors and impact of cardiovascular and renal disease. Cohort
Prospective observational study with serial follow-up investigating predictors and impact of cardiovascular and renal disease.
The Prevention of Renal and Vascular End-stage Disease (PREVEND) study is an epidemiological study that aims to investigate the predictive value of various biomarkers on incidence of cardiovascular and renal disease and the impact of these conditions.
This population cohort has a sample size of 8.592 subjects, enriched for subjects with higher albuminuria. The study started in 1997 in the city of Groningen, the Netherlands with a baseline screening and has 5 follow-up screening rounds with 3 to 4 year intervals. Participants are extremely well pheno- and genotyped.
PREVEND aims to:
- describe the natural course of chronic kidney disease;
- discover risk factors for developing chronic kidney disease;
- discover rick factors for developing cardiovascular disease, including heart failure and atrial fibrillation;
- discover risk factors for developing type 2 diabetes;
- investigate new methods for prevention;
- advocate for the impact of chronic kidney disease.
-
Male and female residents of the city Groningen (the Netherlands) between the age of 27 and 75 years.
-
Please visit the UMCG Research Data Catalogue for more detailed information on our data and samples.
Collected data include among others:
- Anthropometrics
- Medication use
- Questionnaires (incl. comorbidity and neuroticism)
- Extensive laboratory results
- routine clinical chemistry
- innovative biomarkers in plasma, serum and urine
- Cognitive function tests
- ECGs
- Biobanking
- GWAS
- Cardiovascular, renal and diabetes outcome data
- Hospital admissions and reason for admission (NIVEL)
- Mortality data including cause of death (Central Bureau of Statistics)
-
- UMCG department Cardiology;
- UMCG department Clinical Pharmacy and Pharmacology;
- UMCG department Epidemiology;
- UMCG department Internal Medicine (Endocrinology, Nephrology).
-
-
Relevance
How PREVEND benefits to society
Although the PREVEND-cohort does not collect any new data, researchers are now still using the collected data. In total, PREVEND has led to more than 400 publications and dozens of PhD theses. These publications have been cited approximately 16.000 times. The success of PREVEND was also cause for starting Lifelines, the Niercheck and the [email protected] consortium. Moreover, the interest that this study generated for albuminuria as important risk marker for cardiovascular and renal disease led to the new KDIGO definition and classification of chronic kidney disease, that now has also been adopted by the World Health Organization and the International Classification of Diseases.
Contact
University Medical Center Groningen (UMCG)
PREVEND
PO Box 30.001
9700 RB Groningen
The Netherlands
Visiting address
University Medical Center Groningen (UMCG)
Antonius Deusinglaan 1
9713 AV Groningen